Source: Brownstone Institute
by Alan Cassels
“Here’s a good current example of medical irony: the same week that our drug regulator, Health Canada, approved the first generic version of semaglutide — the active ingredient in weight-loss drug Ozempic — a major medical journal published findings highlighting the medication’s troubling connection to eating disorders. The timing couldn’t be more paradoxical: just as this powerful appetite suppressant becomes more accessible and affordable to millions of Canadians, we’re learning more about its potential to trigger dangerous psychological relationships with food.” (05/08/26)